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  “I	   do	   not	   know	   what	   I	   may	   appear	   to	   the	  
world,	  but	   to	  myself	   I	   seem	  to	  have	  been	  only	  
like	   a	   boy	   playing	   on	   the	   sea-­‐shore,	   and	  
diverting	   myself	   in	   now	   and	   then	   finding	   a	  
smoother	   pebble	   or	   a	   prettier	   shell	   than	  
ordinary,	  whilst	  the	  great	  ocean	  of	  truth	  lay	  all	  
undiscovered	  before	  me.”	  
	  
	   	   	   Isaac	  Newton	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Background.	   Temozolomide	   (TMZ)	   is	   a	   methylating	   drug	   that	   is	   commonly	   used	   in	   the	  treatment	  of	  glioma.	  Although	  many	  features	  are	  still	  unclear,	  its	  general	  mechanism	  of	  action	  is	   well	   described.	   TMZ	   induces	   O6-­‐methylguanine	   (O6MeG)	   lesions	   in	   DNA,	   which,	   in	   the	  absence	  of	  repair	  by	  O6-­‐methylguanine	  methyltransferase	  (MGMT),	  mispair	  with	  thymine	  and	  start	   a	   futile	   cycle	   of	   repair-­‐resynthesis	   events.	   The	   resultant	   DNA	   double-­‐strand	   breaks	  (DSBs)	   activate	   the	   components	   of	   G2	   checkpoint,	   and	   cells	   with	   a	   4N	   DNA	   content	  accumulate	   and	   remain	   arrested	   at	   the	   G2/M	   boundary	   for	   several	   days.	   Cell	   death	  subsequently	  occurs	  by	  senescence,	  necrosis,	  or	  mitotic	  catastrophe,	  while	  apoptosis	  has	  been	  ruled	  out	  in	  many	  studies.	  Moreover,	  the	  effect	  of	  multiple	  TMZ	  treatments	  on	  G2	  arrest	  and	  apoptosis	   induction	   is	   not	   clear.	   Repair	   of	   methylating	   drug-­‐induced	   DNA	   lesions	   requires	  monoubiquitination	   of	   PCNA	   and	   FANCD2.	   Loss	   of	   either	   protein	   or	   inhibition	   of	   their	  monoubiquitination	  increases	  drug	  toxicity.	  USP1	  is	  a	  hydrolase	  that	  removes	  monoubiquitin	  from	  PCNA	  and	  FANCD2,	  and	  can	  potentially	  play	  a	  role	  in	  TMZ	  mechanism	  of	  action.	  
Materials	   and	   methods.	   U87,	   U251	   (TMZ-­‐sensitive,	   low	   MGMT),	   and	   GBM8	   (TMZ-­‐resistant,	  high	  MGMT)	  cell	  lines	  were	  used	  for	  experiments.	  The	  treatment	  was	  scheduled	  with	  100µM	  TMZ	  for	  3	  hours	  for	  1,	  2,	  or	  3	  consecutive	  days.	  Cell	  cycle	  progression	  was	  studied	  with	  both	  FACS-­‐based	   analysis	   and	   a	   novel	   time-­‐lapse	   microscopic	   real-­‐time	   analysis	   using	   FUCCI	  (Fluorescent	   Ubiquitination-­‐based	   Cell	   Cycle	   Indicator),	   and	   apoptosis	   was	   measured	   with	  FACS-­‐based	  Annexin	  V-­‐PI	   analysis.	   To	   address	   the	  possible	   role	   of	  USP1	   in	  TMZ	   action,	  we	  examined	  expression	  of	  USP1	  at	  the	  mRNA	  levels	  in	  expression	  microarray	  databases	  derived	  from	  primary	  GBM.	  We	   also	   used	   siRNA	   targeting	  USP1	   to	  modulate	  USP1	   expression,	   and	  studied	   the	   effect	   of	   USP1	   downregulation	   on	   TMZ-­‐induced	   G2	   arrest,	   cell	   death,	   and	  clonogenicity.	  	  
Results.	  	  Compared	  to	  single	  treatment,	  multiple	  TMZ	  treatments	  cause	  a	  significant	  reduction	  of	   clonogenicity	   in	   TMZ-­‐sensitive	   cells	   and	   induce	   a	   significant	   increase	   of	   apoptosis,	  particularly	  in	  a	  late	  stage.	  However,	  multiple	  treatments	  don’t	  have	  any	  major	  effect	  on	  cell	  cycle	  profile.	  Time-­‐lapse	  microscopic	  analysis	  with	  FUCCI	  system	  showed	  that	  TMZ-­‐sensitive	  glioma	   cells	   arrest	   at	   the	   G2	   checkpoint	   for	   less	   than	   48	   hours	   and,	   in	   the	   presence	   of	   an	  
	  	  
VI	  
activated	  G2	  checkpoint,	   they	  replicate	   their	  DNA	  without	  cellular	  division,	   re-­‐enter	   the	  cell	  cycle	   at	   the	   next	   G1	   phase,	   and	   repeat	   the	   cycle,	   ultimately	   giving	   rise	   to	   polyploid	   cells.	  siRNA-­‐mediated	  suppression	  of	  USP1	  had	  no	  effect	  on	  cell	  cycle	  progression	  or	  the	  extent	  of	  temozolomide-­‐induced	  G2	  arrest.	  However,	  while	  USP1	  knockdown	  alone	  had	  minimal	  effect	  on	  cell	  death,	  it	  increased	  temozolomide-­‐induced	  loss	  of	  clonagenicity	  both	  in	  TMZ-­‐sensitive	  and	  TMZ-­‐resistant	  cells.	  Further	  examination	  of	   the	  mechanism	  of	  cell	  death	  suggested	   that	  while	  control	  cells,	  control	  cells	  exposed	  to	  TMZ,	  or	  USP1-­‐suppressed	  cells	  rarely	  underwent	  apoptotic	   cell	   death,	   temozolomide-­‐treated	   cells	   in	   which	   USP1	   levels	   were	   suppressed	  underwent	  high	  rates	  of	  apoptosis.	  	  	  




Introduzione.	  La	  temozolomide	  (TMZ)	  è	  un	  farmaco	  alchilante	  frequentemente	  utilizzato	  nella	  chemioterapia	   dei	   gliomi.	   Nonostante	   molti	   aspetti	   siano	   ancora	   enigmatici,	   il	   suo	  meccanismo	  di	  azione	  generale	  è	  ben	  noto.	  La	  TMZ	  induce	  metilazione	  della	  guanina	  nel	  DNA	  (O6MeG)	   che,	   in	   assenza	   di	   riparazione	   ad	   opera	   di	   O6-­‐methylguanine	   methyltransferase	  (MGMT),	   si	   appaia	   con	   una	   timina	   innescando	   un	   ciclo	   futile	   di	   riparazione	   e	   risintesi.	   Ne	  risultano	  rotture	  del	  DNA	  a	  doppio	  filamento	  (DSBs)	  che	  attivano	  i	  componenti	  del	  checkpoint	  in	  G2,	  e	  le	  cellule	  con	  DNA	  4N	  si	  accumulano	  e	  arrestano	  in	  G2	  per	  parecchi	  giorni.	  Le	  cellule	  muoiono	  poi	  per	  senescenza,	  necrosi,	  o	  catastrofe	  mitotica,	  mentre	  l’apoptosi	  è	  stata	  a	  lungo	  negata.	  Inoltre	  non	  è	  chiaro	  l’effetto	  di	  somministrazioni	  multiple	  di	  TMZ	  sull’arresto	  in	  G2/M	  e	  sull’induzione	  di	  apoptosi.	  La	  riparazione	  delle	  lesioni	  al	  DNA	  causate	  dai	  farmaci	  alchilanti	  richiede	   la	  monoubiquitinazione	  di	   PCNA	  e	  FANCD2;	   la	   perdita	  di	   una	  delle	   due	  proteine	  o	  l’inibizione	  della	  loro	  monoubiquitinazione	  potenzia	  la	  tossicità	  indotta	  dagli	  agenti	  metilanti.	  USP1	  è	  una	  idrolasi	  in	  grado	  di	  rimuovere	  la	  monoubiquitina	  da	  PCNA	  e	  FANCD2,	  e	  per	  questo	  può	  essere	  un	  regolatore	  della	  risposta	  alla	  TMZ.	  
Materiali	  e	  metodi.	  Sono	  state	  utilizzate	  le	  linee	  cellulari	  U87,	  U251	  (TMZ-­‐sensibili,	  bassi	  livelli	  di	  MGMT)	  e	  GBM8	  (TMZ-­‐resistenti,	  alti	  livelli	  di	  MGMT).	  Il	  protocollo	  di	  trattamento	  prevede	  1,	  2	  o	  3	  dosi	  di	  TMZ	  100µM	  per	  3	  ore.	  La	  progressione	  nel	  ciclo	  cellulare	  è	  stata	  studiata	  sia	  con	   FACS	   sia	   con	   una	   nuova	   tecnica	   di	   microscopia	   time-­‐lapse	   in	   tempo	   reale	   (FUCCI,	  Fluorescent	  Ubiquitination-­‐based	  Cell	  Cycle	  Indicator),	  mentre	  l’apoptosi	  è	  stata	  verificata	  al	  citofluorimetro	   con	   il	  metodo	   	   dell’annessina	   V-­‐Propidio	   Ioduro.	   	   Per	   verificare	   il	   possibile	  ruolo	  di	  USP1	  nell’azione	  della	  TMZ,	  dopo	  aver	  esaminato	  su	  databases	  di	  mRNA	  microarray	  l’espressione	   di	   USP1	   nei	   glioblastomi,	   le	   cellule	   sono	   state	   transfettate	   con	   RNA	   a	  interferenza	  contro	  USP1	  o	  di	  controllo.	  È	  quindi	  stato	  studiato	  l’effetto	  della	  soppressione	  dei	  livelli	  di	  USP1	  sull’arresto	  in	  G2/M,	  la	  morte	  cellulare	  e	  la	  clonogenicità	  indotte	  dalla	  TMZ.	  
Risultati.	   Trattamenti	   multipli	   con	   TMZ	   riducono	   la	   clonogenicità	   delle	   cellule	   di	   glioma	  sensibili	   al	   farmaco	   in	  maniera	  significativamente	  superiore	   rispetto	  al	   trattamento	  singolo,	  non	   modificano	   l’entità	   dell’arresto	   in	   G2,	   mentre	   inducono	   un	   significativo	   aumento	  dell’apoptosi	   in	   particolare	   in	   fase	   tardiva.	   L’analisi	   in	   time-­‐lapse	   con	   il	   sistema	   FUCCI	   ha	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mostrato	   che	   le	   cellule	   sensibili	   alla	   TMZ	   subiscono	   un	   arresto	   in	   G2	   inferiore	   alle	   48	   ore.	  Inoltre,	  in	  presenza	  di	  attivazione	  del	  checkpoint	  in	  G2,	  replicano	  il	  DNA	  ma	  non	  si	  dividono,	  rientrando	  nel	   ciclo	   cellulare	   in	  G1	  e	  dando	  origine	  a	   cellule	  poliploidi.	   La	   soppressione	  dei	  livelli	   di	   USP1	   da	   sola	   ha	   effetti	  minimi	   sulla	   progressione	   del	   ciclo	   cellulare	   e	   sulla	  morte	  cellulare	   sia	   nelle	   cellule	   sensibili	   che	   in	   quelle	   resistenti	   alla	   TMZ.	   Allo	   stesso	   modo,	   la	  soppressione	   dei	   livelli	   di	   USP1	   non	   altera	   l’entità	   dell’arresto	   in	   G2/M	   indotto	   dalla	   TMZ.	  Tuttavia	   il	   knockdown	   di	   USP1	   sorprendentemente	   incrementa	   la	   perdita	   di	   clonogenicità	  indotta	  dalla	  TMZ	  sia	  nelle	  cellule	  sensibili	  che	  in	  quelle	  resistenti.	  A	  differenza	  delle	  cellule	  di	  controllo	  in	  cui	  USP1	  è	  stato	  soppresso,	  o	  di	  quelle	  con	  normale	  espressione	  di	  USP1	  e	  trattate	  con	  TMZ,	  le	  cellule	  USP1-­‐knockdown	  trattate	  con	  TMZ	  subiscono	  un’alta	  percentuale	  di	  morte	  per	  apoptosi.	  
Conclusioni.	   I	   risultati	   dei	   nostri	   studi	   hanno	   mostrato	   che	   il	   trattamento	   delle	   cellule	   di	  glioma	  con	  TMZ	  può	  indurre	  apoptosi,	  e	  che	  questa	  è	  evidenziabile	  già	  dopo	  3	  giorni,	  sebbene	  diventi	   significativa	   solo	   tardivamente.	   Trattamenti	   multipli	   non	   modificano	   l’entità	  dell’arresto	  in	  G2,	  ma	  aumentano	  significativamente	  l’apoptosi.	  Inoltre	  gli	  studi	  di	  time-­‐lapse	  permettono	  di	  proporre	  un	  nuovo	  meccanismo	  di	  azione	  per	  la	  TMZ,	  diverso	  da	  quello	  finora	  comunemente	   accettato,	   con	   significative	   implicazioni	   sullo	   sviluppo	   della	   resistenza	   al	  farmaco.	   La	   deubiquitinasi	   USP1,	   piuttosto	   che	   impedire	   l’attivazione	   di	   PCNA	   e	   FANCD2	   e	  inibire	   in	  questo	  modo	   la	  riparazione	  del	  danno	  al	  DNA	  indotto	  dagli	  agenti	  metilanti,	  come	  indirettamente	   suggerito	   da	   studi	   precedenti,	   sembra	   invece	   sopprimere	   vie	   apoptotiche	  latenti	  e	  proteggere	  le	  cellule	  dall’apoptosi	  indotta	  dalla	  TMZ.	  La	  soppressione	  di	  USP1	  o	  delle	  vie	  controllate	  da	  USP1	  può	  rappresentare	  un	  modo	  per	  incrementare	  il	  potenziale	  citotossico	  della	  TMZ	  e	  per	  sensibilizzare	  GBM	  prima	  resistenti.	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1.	  Introduction	  
Glioblastoma	   multiforme	   WHO	   grade	   IV	   (GBM)	   is	   one	   of	   the	   most	   aggressive	   human	  malignant	  diseases	  and	  the	  most	  frequent	  primary	  tumor	  of	  the	  central	  nervous	  system.	  It	  has	  an	  incidence	  of	  4-­‐5/100000	  inhabitants	  per	  year	  in	  Europe	  and	  North	  America	  [23,56].	  GBM	  has	   a	   dismal	   prognosis,	   with	   a	   survival	   rate	   less	   than	   10%	   two	   years	   after	   diagnosis,	   and	  lower	  than	  3%	  five	  years	  after	  diagnosis	  [10,17,20].	  Currently,	   there	   are	   several	   treatment	   options	   for	   GBM.	   Of	   course	   surgery	   is	   the	   first-­‐line	  therapy.	  It	  is	  necessary	  to	  assess	  the	  correct	  diagnosis,	  improve	  symptoms	  due	  to	  mass	  effect,	  enhance	  radiotherapy	  (RT)	  and	  chemotherapy	  (CT)	  effects,	  and	  ultimately	  prolong	  patients’	  survival.	   Moreover,	   many	   researchers	   have	   indicated	   that	   the	   extent	   of	   resection	   is	   of	  prognostic	   value	   [83].	   However,	   considering	   a	   GBM	   has	   an	   average	   of	   1011	   cells,	   a	   99%	  resection	  of	   the	   tumor	  would	   reduce	   the	  amount	  of	   cells	   to	  109	   cells.	  Therefore	   it’s	   evident	  that	  surgery	  cannot	  be	  the	  ultimate	  treatment	   for	  such	  a	  disease.	  RT	  can	  potentially	   further	  reduce	   the	   tumor	   mass	   to	   107	   cells.	   However,	   the	   best	   chances	   to	   improve	   survival	   are	  expected	  from	  CT	  agents.	  It	  has	  been	  shown	   that	   the	  alkylating	  drug	   temozolomide	   (TMZ)	  prolongs	  patients’	   survival	  when	   it	   is	   administered	  during	   and	  after	  RT	  as	  part	   of	   the	   first	   line	   therapy	   [89].	  TMZ	   is	   a	  methylating	  prodrug	  derived	  from	  imidazotriazine.	  It	  is	  orally	  administered	  and	  has	  a	  100%	  biodisponibility	   [8,66].	  The	  compound	   is	  spontaneously	  hydrolyzed	   to	   the	  active	  product	  5-­‐(3-­‐methyltriazen-­‐1-­‐yl)imidazole-­‐4-­‐carboxamide	   (MTIC)	   at	   physiological	   pH	   [22,94].	   MTIC	  methylates	   DNA	   at	   nucleophylic	   centres	   creating	   a	   variety	   of	   DNA	   adducts,	   including	   N7-­‐methylguanine,	  O6-­‐methylguanine,	  and	  N3-­‐methyladenine	  [22]	  (Figure	  1).	  All	  of	  these	  adducts	  have	  a	  role	  in	  the	  cytotoxic	  potential	  of	  TMZ.	  However,	  the	  best	  evidence	  to	  date	  indicates	  that	  the	  mutagenic	  and	  toxic	  effects	  of	  TMZ	  are	  directly	  related	  to	  methylation	  of	  the	  O6	  position	  of	  guanine,	  and	  to	  the	  cellular	  response	  to	  the	  lesion	  [31].	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   Figure	   1.	   Temozolomide	   and	   its	   chemical	   reaction	   with	   DNA.	   Temozolomide	   acts	   as	   a	   prodrug,	  	   transporting	  a	  methylating	  agent	  (the	  methyldiazonium	  ion)	  to	  guanine	  bases	  within	  the	  major	  groove	  of	  	   DNA.	   The	   mechanism	   of	   activation	   involves	   chemical	   hydrolytic	   cleavage	   of	   the	   tetrazinone	   ring	   at	  	   physiological	   pH	   to	   give	   the	   unstable	  monomethyl	   triazene,	   which	   then	   undergoes	   further	   cleavage	   to	  	   liberate	   the	   stable	   5-­‐aminoimidazole-­‐4-­‐carboxamide	   and	   the	   highly	   reactive	   methyldiazonium	  	   methylating	  species.	  (Modified	  from	  Neidle	  S	  and	  Thurston	  DE,	  2005	  [65]).	  
O6G	   methylation	   (O6MeG),	   the	   most	   relevant	   TMZ-­‐induced	   lesion,	   is	   repaired	   by	   O6-­‐methylguanine-­‐DNA	  methyltransferase	   (MGMT),	   which	   directly	   transfers	   the	  methyl	   group	  from	   guanine	   oxygen	   to	   a	   cysteine	   residue	   (Cys145)	   on	   the	  MGMT	  molecule.	   This	   reaction	  irreversibly	   inactivates	   the	   enzyme	   [32,35,74-­‐76].	   In	   those	   cells	   where	   MGMT	   is	   low	   or	  absent,	   O6MeG	   is	   not	   repaired,	   and	   consequently	   mispairs	   with	   thymine	   (T)	   instead	   of	  cytosine	   (C)	   during	   DNA	   replication	   [51].	   Tumor	   cells	   with	   a	   competent	   mismatch-­‐repair	  system	  (MMR)	  are	  able	  to	  remove	  the	  T	  residue,	  but	  they	  insert	  again	  a	  T	  because	  MMR	  does	  not	   repair	   the	   guanine	  methylation	   [1,24].	   As	   a	   consequence,	   a	   futile	   MMR	   cycle	   develops	  [38,50].	  This	   interferes	  during	   the	   following	  DNA	  replication	  cycle	   leading	   to	  double-­‐strand	  breaks	  (DSBs)	  and	  ultimately	  to	  cytotoxic	  effect	  [70]	  (Figure	  2).	  For	  this	  reason,	  an	  effective	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therapy	  requires	  low	  MGMT	  levels,	  and	  a	  proficient	  post-­‐replicative	  MMR	  system.	  Cells	  with	  high	   MGMT	   content	   or	   an	   impaired	   MMR	   system	   show	   a	   reduced	   sensitivity	   to	   alkylating	  agents.	   MGMT	   level	   significantly	   varies	   in	   tumor	   cells.	   Brain	   tumors	   usually	   express	   low	  MGMT	  levels	  [6,15,78,86],	  likely	  due	  to	  the	  methylation	  of	  MGMT	  gene	  promoter	  [27,28].	  	  
	  	   Figure	   2.	   Temozolomide	   methylates	   DNA	   producing	   about	   a	   dozen	   of	   adducts.	   One	   of	   them,	   O6MeG,	  	   although	   representing	   only	   5%	   of	   all	   adducts,	   is	   the	   most	   damaging	   lesion	   for	   the	   cell.	   Guanine	   O6-­‐	   alkylation	  is	  repaired	  by	  MGMT	  enzyme.	  When	  MGMT	  is	  absent,	  a	  mismatch	  between	  O6MeG	  and	  thymine	  	   activates	   the	   Mismatch	   Repair	   System	   (MMR).	   MMR	   can	   act	   only	   on	   the	   most	   recently	   synthesized	  	   filament	   and	   is	   unable	   to	   remove	   the	   methylation	   on	   guanine.	   This	   causes	   futile	   MMR	   cycles	   that	   ultimately	  lead	  to	  DSBs	  and	  eventually	  to	  cell	  death.	  
Although	  the	  cellular	  response	  to	  methylating	  agents	  mainly	  depends	  on	  DNA	  repair	  systems,	  it	  has	  been	  shown	  that	  it’s	  also	  related	  to	  cell	  cycle	  G2-­‐checkpoint	  [41].	  TMZ-­‐induced	  double-­‐
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strand	   breaks	   (DSBs)	   trigger	   Chk1	   and	  Chk2	   through	   the	   activation	   of	   ataxia-­‐telangiectasia	  mutated	  (ATM)	  and	  ataxia-­‐telangiectasia	  and	  Rad3-­‐related	  (ATR)	  phosphoinositide	  3-­‐kinase-­‐related	  kinases.	  Chk1	  phosphorylate	  Cdc25C	  phosphatase,	  which	  is	  therefore	  inactivated,	  and	  consequently	  Cdc2	  remains	  bound	  to	  Cyclin	  B	  in	  an	  inactive,	  phosphorylated	  state	  [42].	  The	  end	  result	  of	  DNA	  damage-­‐induced	  Chk1	  activation	  is	  G2/M	  arrest,	  which	  is	  supposed	  to	  give	  cells	  more	  time	  to	  repair	  the	  DNA	  damages	  caused	  by	  the	  drug	  before	  entry	  into	  mitosis	  [13].	  More	  recently	  Wee1,	  which	  is	  responsible	  for	  Cdc2	  phosphorylation,	  has	  been	  identified	  as	  a	  major	   determinant	   of	   the	   DNA	   damage-­‐induced	   G2	   arrest	   in	   GBM	   cells	   [60].	   Aurora	   A	   and	  Polo-­‐like	  kinase	  1	  (Plk1)	  have	  also	  been	  implied	  in	  promoting	  entry	  and	  progression	  through	  mitosis,	  and	  participating	  in	  a	  feedback	  activating	  loop	  with	  Cdk1	  [9,57,96].	  TMZ	  ultimately	  pushes	  human	  glioma	  cells	  towards	  different	  fates.	  Of	  course,	  cells	  can	  survive	  the	   treatment,	   and	   this	   is	  particularly	   true	   for	   cells	  undergoing	   a	  prolonged	  G2	  arrest	   [41].	  Conversely,	   TMZ	   can	   induce	   cell	   death	   through	   necrosis	   or	   mitotic	   catastrophe	   in	   a	   p53-­‐independent	  manner,	  or	  a	  G2/M	  arrest	  followed	  by	  senescence	  [42].	  Another	  study	  proposed	  that	  TMZ	  can	   induce	  autophagy	  but	  not	  apoptosis	   in	  glioma	  cells	   [49,64],	  while	  glioma	  cells	  grown	  as	  spheroids	  can	  undergo	  apoptosis	  after	  treatment	  with	  alkylating	  agents	  [36].	  Most	  of	   the	   published	   studies	   excluded	   apoptosis	   as	   a	   consequence	   of	   TMZ	   treatment	   in	   glioma	  cells.	  However,	  a	  more	  recent	  paper	  showed	  that	  human	  glioma	  cells	  could	  undergo	  apoptosis	  in	  a	  dose-­‐	  and	  time-­‐dependent	  manner	  after	  treatment	  with	  methylating	  agents	  creating	  the	  specific	  O6MeG	  DNA	  lesion,	   in	  a	  p53-­‐dependent	  way	  [79].	  It	  has	  been	  proposed	  that	  O6MeG-­‐induced	  DSBs	  can	  activate	  the	  ATM/ATR-­‐Chk1	  pathway,	  and	  stabilize	  p53.	  This	  would	  induce	  an	   increased	   expression	   of	   Fas	   receptor	   (FasR),	   a	   Caspase	   8	   activation,	   and	   apoptosis	  induction.	   Apoptosis	   in	   glioma	   after	   TMZ	   treatment	   can	   also	   be	   induced	   through	   a	   p53-­‐independent	   pathway,	   involving	   Bcl-­‐2	   degradation	   and	   Caspase	   9	   activation	   [79].	   The	  described	   model	   implies	   that	   DNA	   replication	   and	   cellular	   proliferation	   are	   essential	   for	  O6MeG-­‐induced	  apoptosis	  in	  glioma	  cells.	  Although	   apoptosis	   induced	   by	   O6-­‐methylating	   agents	   has	   been	   extensively	   described	   in	  several	  experimental	  systems	  as	  rodent	  cell	  lines	  [70],	  lymphoblastic	  cells	  [25,40],	  and	  human	  peripheral	   lymphocytes	  [80],	   it	   is	  still	  enigmatic	   in	  brain	  gliomas,	  especially	   in	  relation	  with	  treatment	  protocols	  used	  in	  clinical	  practice,	  that	  are	  very	  often	  different	  compared	  to	  those	  used	  in	  the	  laboratory.	  Despite	  the	  well-­‐known	  effectiveness	  of	  O6-­‐alchylating	  drugs	  in	  glioma	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treatment,	  the	  median	  survival	  for	  GBM	  patients	  is	  still	  very	  low	  (12-­‐14	  months)	  [21].	  For	  this	  reason,	   an	   improvement	   of	   glioma	   therapy	   is	   urgently	   needed.	   The	   possibility	   to	   induce	  apoptosis	   in	   gliomas	   with	   TMZ	   is	   particularly	   interesting,	   because	   it	   represents	   a	   finely	  controlled	   cell-­‐death	  pathway.	  Moreover,	   it	   can	  avoid	   the	   inflammatory	   response	  activation	  and	  its	  related	  side	  effects.	  Therefore,	  the	  first	  aim	  of	  our	  work	  was	  to	  verify	  the	  ability	  of	  TMZ	  to	  induce	  cell	  cycle	  arrest	  and	  apoptosis	  in	  glioma	  cell	  lines,	  with	  comparable	  TMZ	  dosage	  that	  is	  used	  on	  patients	  and	  fractionated	  into	  multiple	  treatments,	  as	   in	  clinical	  practice.	  Then	  we	  tried	  to	  better	  explore	  the	  relation	  between	  G2	  checkpoint	  and	  apoptosis.	  However,	  fluorescent-­‐activated	  cell	  sorting	  (FACS)-­‐based	  cell	  cycle	  analysis	  provides	  just	  a	  static	  view	  of	  cell	  cycle	  profile,	  and	  considers	  the	  whole	  cells	  population.	  In	  order	  to	  focus	  on	  the	  single-­‐cell	  level,	  and	  to	  analyze	  cell	  cycle	  in	  a	  dynamic	  setting,	  we	  used	  the	  FUCCI	  (Fluorescent	  Ubiquitination-­‐based	  Cell	  Cycle	  Indicator)	  technique,	   a	   new	   set	   of	   chimeric	   proteins,	   which	   are	   able	   to	   visualize	   and	   track	   cell	   cycle	  progression	  in	  cultured	  cells	  [81,82].	  This	  method	  exploits	  cell	  cycle-­‐dependent	  proteolysis	  of	  the	   ubiquitination	   oscillators,	   Cdt1	   and	   Geminin,	   to	   specifically	   mark	   the	   G1/S/G2/M	  transition	  in	  living	  cells.	  Cdt1	  and	  Geminin	  are	  substrates	  of	  the	  ubiquitin	  E3	  ligase	  complexes	  APCCdh1	  and	  SCFSkp2,	  respectively	  [99].	  While	  APCCdh1	   is	  most	  active	  during	  G1	  phase,	  SCFSkp2	  functions	   primarily	   during	   S,	   G2,	   and	   early	   M	   phases	   [3,55,58,59,91,101].	   Consequently,	  Geminin	   and	   Cdt1	   are	   specifically	   degraded	   during	   G1	   and	   S/G2/M,	   respectively	   [69].	  Therefore,	   by	   fusing	   the	   red-­‐	   and	   green-­‐emitting	   fluorescent	   proteins	  monomeric	   Kusabira	  Orange	  1	  (mKO1)	  and	  monomeric	  Azami	  Green	  2	  (mAG2)	  to	  Cdt1	  and	  Geminin,	  respectively,	  it	   is	   possible	   to	   achieve	   striking	   contrast	   between	   the	  nuclei	   of	   cells	   in	  G1	  phase	   (red)	   and	  those	  of	  cells	  in	  S/G2/M	  (green).	  With	  the	  aim	  of	  increasing	  the	  cytotoxic	  response	  to	  TMZ,	  we	  studied	  its	  potential	  interaction	  with	  USP1	   (ubiquitin	   specific	  peptidase	  1).	  USP1	   is	   an	  ubiquitin-­‐hydrolase,	  which	   is	   able	   to	  remove	  a	  single	  ubiquitin	  molecule	  from	  target-­‐proteins	  like	  PCNA	  (proliferating	  cell	  nuclear	  antigen)	  and	  FANCD2	  (Fanconi	  anemia	  D2	  protein)	  [45,68].	  The	  catalytic	  activity	  of	  USP1	   is	  largely	   increased	   upon	   formation	   of	   a	   complex	  with	   USP1-­‐associated	   factor	   1	   (UAF1)	   [98].	  PCNA	  ubiquitination	  is	  central	  to	  the	  normal	  DNA	  damage	  response	  process	  in	  eukariotes	  [4].	  Monoubiquitination	  of	  PCNA	  is	  essential	  for	  translesion	  synthesis	  that	  promotes	  lesion	  bypass	  synthesis	   across	   the	  damaged	  base	   [48,104].	   It	  has	  been	   shown	   that	  USP1	  down-­‐regulation	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following	  DNA	  damage	  is	  associated	  with	  the	  activation	  of	  PCNA-­‐	  and	  FANCD2-­‐related	  DNA-­‐repair	   systems,	   with	   the	   result	   of	   an	   increased	   cells	   survival	   [62,67,72].	   Conversely,	   a	  persistent	   deubiquitination	   of	   PCNA	   can	   increase	   the	   cytotoxic	   effect	   of	   methyl-­‐methane-­‐sulfonate	  (MMS),	  an	  alkylating	  agent	  [67].	  This	  effect	  is	  particularly	  interesting,	  as	  MMS	  is	  able	  to	   generate,	   besides	   7MeG	   and	   3MeA,	   also	   a	   small	   amount	   of	   O6MeG,	   which	   is	   the	   most	  biologically-­‐relevant	   lesion	   induced	  by	  TMZ.	  Because	  USP1	  plays	   important	  roles	   in	  the	  two	  essential	  DNA	  damage	   response	   pathways,	   it	   represents	   a	   promising	   target	   to	   improve	   the	  efficacy	  of	  the	  commonly	  used	  DNA	  damaging	  drugs	  [14].	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2.	  Materials	  and	  Methods	  
2.1	  Cell	  cultures	  Human	  GBM	  U87	  cell	   line	  was	  obtained	   from	  the	  American	  Type	  Culture	  Collection	  (ATCC),	  human	  GBM	  U251	  cell	  line	  and	  primary	  GBM8	  cell	  line	  were	  obtained	  from	  the	  Tissue	  Core	  of	  the	   Brain	   Tumor	   Research	   Center,	   University	   of	   California,	   San	   Francisco.	   U87	   is	   a	   PTEN-­‐mutated,	  p53-­‐wild	  type	  cell	  line,	  U251	  is	  PTEN-­‐mutated,	  and	  p53-­‐wild	  type,	  xenograft-­‐derived	  GBM8	   is	   PTEN-­‐wild	   type	   and	   P53-­‐mutated.	   All	   cell	   lines	   were	   growth	   in	   DMEM-­‐HG	  (Dulbecco’s	  modified	  Eagle’s	  medium-­‐High	  Glucose,	  GIBCO)	  supplemented	  with	  10%	  bovine	  fetal	   serum	   and	   1%	   Penicillin/Streptomycin	   (GIBCO/BRL).	   Depending	   on	   the	   experiment,	  cells	   have	   been	   grown	   in	   100mm	   dishes,	   6-­‐well	   plates,	   or	   2-­‐well	   coverglass	   chambers	  (Nalgene	   Nunc)	   and	   incubated	   at	   37°C	   in	   95%	   humidified	   air	   with	   5%	   CO2.	   All	   the	  experiments	  were	  carried	  on	  50-­‐70%	  confluent	  cell	  cultures.	  
2.1.1	  TMZ	  treatment	  TMZ	   (Sigma,	   St.	   Louis,	   MO,	   USA)	   was	   dissolved	   into	   dimethyl-­‐sulfoxyde	   (DMSO;	   Sigma,	   St.	  Louis,	  MO,	  USA),	  filtered,	  aliquoted,	  and	  stored	  at	  -­‐20°C.	  GBM	  cell	  lines	  were	  treated	  with	  TMZ	  100µM	  for	  3	  hours.	  The	  wells	  were	  washed	  with	  PBS	  (phosphate-­‐buffered	  saline)	  and	  filled	  with	   new	  DMEM.	   In	  multiple	   treatment	   experiment,	   TMZ	  was	   administered	   in	   consecutive	  days.	  Cells	  were	  then	  trypsinized	  and	  harvested	  at	  3	  and	  7	  days	  after	  treatment.	  
2.1.2	  Clonogenicity	  assays	  Treated	   and	   control	   cells	   were	   plated	   at	   different	   concentrations	   (2000,	   5000,	   10000,	   and	  20000	  cells/well)	  in	  6-­‐well	  plates,	  and	  incubated	  at	  37°C	  with	  a	  5%	  CO2.	  Fourteen	  days	  later,	  cells	  were	  stained	  with	  Methylen	  Blue	  (Sigma).	  Colonies	  of	  more	  than	  50	  cells	  were	  counted.	  Each	  experiment	  had	  been	  repeated	  at	  least	  3	  times.	  
2.1.3	  siRNA	  transfection	  Cells	  were	  plated	  into	  6-­‐well	  plates	  in	  order	  to	  obtain	  60-­‐70%	  confluency	  after	  24	  hours.	  Then	  they	   were	   transfected	   with	   either	   USP1-­‐siRNA	   500nm	   (Thermo	   Scientific	   Dharmacon	   ON-­‐
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TARGETplus	   SMARTpool)	   or	   with	   Control-­‐siRNA	   200nM	   (Thermo	   Scientific	   Dharmacon	  Accell)	   following	   the	   protocol.	   DharmaFECT	   4	   Transfection	   Reagent	   (Thermo	   Scientific	  Dharmacon)	  was	  used.	  Cells	  were	  then	  treated	  with	  TMZ	  after	  a	  72-­‐hour	  incubation	  at	  37°C	  and	  5%	  CO2.	  
2.1.4	  Creation	  of	  FUCCI-­‐encoding	  glioma	  cells	  In	   order	   to	   clone	   FUCCI	   (Fluorescent	   Ubiquitination-­‐based	   Cell	   Cycle	   Indicator;	   MBL	  International	  Corporation,	  Woburn,	  MA,	  USA)	  plasmids	  (a	  fusion	  protein	  of	  a	  fragment	  of	  Cdt1	  with	   monomeric	   Kusabira-­‐Orange	   2,	   mKO2-­‐hCdt1,	   and	   a	   fusion	   protein	   of	   a	   fragment	   of	  Geminin	   with	   monomeric	   Azami-­‐Green	   1,	   mAG1-­‐hGem),	   DH5a	   competent	   cells	   were	   first	  transformed	  and	  selected	  with	  kanamycin.	  Amplified	  plasmids	  were	   then	  purified	  using	   the	  QIAfilter	   Plasmid	  Midi	   kit	   (Qiagen,	   Valencia,	   CA,	   USA).	   The	   plasmids	   presence	  was	   verified	  with	  electrophoresis	  after	  digestion	  with	  XhoI	  restriction	  enzyme.	  Glioma	   cells	   were	   plated	   to	   obtain	   60-­‐70%	   confluency	   after	   24	   hours.	   To	   develop	   cells	  expressing	  both	  vectors,	  glioma	  cells	  were	  serially	  infected	  with	  plasmid	  constructs	  encoding	  each	  protein	  (400ng/ml	  plasmid	  in	  10cm	  plate	  +	  Fugene	  6	  Transfection	  Reagent).	  Cells	  were	  incubated	   at	   37°C	   and	   5%	   CO2	   for	   48	   hours.	   Transfected	   cells	   were	   selected	   in	   200µg/ml	  G418	  (Neomycin)	   for	  5	  days.	   In	  order	   to	  select	  only	   the	  double	   transfected	  cells,	   cells	  were	  subjected	   to	   FACS	   sorting	   (Fluorescence-­‐activated	   cell	   sorting,	   FACS	   Aria	   III,	   Becton	  Dickinson,	  San	  Jose,	  California).	  Cells	  expressing	  Geminin	  (red)	  were	  first	  sorted,	  plated,	  and	  regrown	  for	  1	  week	  after	  which	  cells	  expressing	  Cdt1	  (green)	  were	  similarly	  FACS	  sorted.	  The	  two	  detection	  channels	  we	  used	  for	  the	  FUCCI	  dyes	  were	  FITC	  (488nm	  laser	  with	  530/30nm	  filter)	  and	  DS	  Red	  (561nm	  laser	  with	  670/30nm	  filter).	  The	  identity	  of	  the	  double-­‐sorted	  cells	  was	  then	  verified	  with	  Spinning	  Disk	  Confocal	  Microscopy	  and	  time-­‐lapse	  imaging,	  and	  the	  G1	  and	   G2	   specificity	   of	   the	   constructs	   was	   confirmed	   by	   measuring	   the	   DNA	   content	   of	  transfected	  cells	  with	  the	  FACS	  Aria	  II	  Flow	  Cytometer.	  
2.2	  Cytometry	  Cytometry	   was	   used	   to	   study	   cell	   cycle	   arrest,	   apoptosis,	   and	   to	   select	   FUCCI-­‐transfected	  glioma	  cells.	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2.2.1	  Cell	  cycle	  analysis	  TMZ-­‐treated	   and	   control	   cells	   were	   harvested	   after	   trypsinization,	   along	  with	   supernatant.	  After	  3	  PBS	  washing	  cycles	  and	  centrifugation	  at	  800	  rpm	  for	  5	  minutes,	  cells	  were	   fixed	   in	  ethanol	  70%	  (vol/vol)	  and	  stored	  at	  -­‐20°C.	  Cells	  were	  then	  washed	  with	  PBS	  and	  incubated	  in	  PBS	  with	  Propidium	   Iodide	   (PI)	  40µg/ml	  and	  RNase	  A	  200µg/ml	   for	  15	  minutes	   in	  dark	  at	  room	   temperature.	   Samples	   were	   processed	   with	   FACS	   Calibur	   and	   data	   analyzed	   with	  CellQuest	  Pro	  software.	  At	  least	  104	  cells	  were	  collected	  for	  each	  sample,	  and	  in	  triplicate.	  G1,	  S,	   and	   G2	   populations	   were	   analyzed	   with	   ModFit	   LT	   software	   (Verity	   Software	   House,	  Topsham,	  ME,	  USA).	  
2.2.2	  Apoptosis	  analysis	  Apoptosis	  after	  TMZ	  treatment	  was	  measured	  using	  Annexin	  V-­‐Propidium	  Iodide	  technique.	  TMZ	   treated	   and	   control	   cells	   were	   harvested	   after	   trypsinization	   along	   with	   supernatant.	  After	  3	  washing	  cycles	  in	  PBS	  and	  centrifugation	  at	  800	  rpm	  for	  5	  minutes,	  cells	  were	  tested	  with	  ApopNexin	  FITC	  kit	  (Millipore,	  Billerica,	  MA,	  USA)	  following	  the	  provided	  protocol.	  FACS	  Calibur	  (Becton	  Dickinson,	  San	  Jose,	  California)	  was	  used	  for	  cell	  detection.	  At	  least	  104	  cells	  were	   collected	   for	   each	   sample,	   and	   in	   triplicate.	   Vital,	   apoptotic,	   and	   necrotic	   cells	   were	  analyzed	  with	  FlowJo	  8.8.6	  software	  (Ashland,	  OR,	  USA).	  Annexin	  V	  is	  a	  protein,	  which	  has	  a	  very	  high	  affinity	  for	  membranes	  containing	  the	  negatively	  charged	  phospholipid	  phosphatidylserine	  (PS).	  PS	   is	  exposed	  on	  the	  outer	  membrane	  at	   the	  very	  beginning	  of	  apoptosis,	  before	  DNA	  fragmentation.	  For	  this	  reason,	  Annexin	  V	  staining	  is	  considered	  the	  method	  of	  choice	  to	  detect	  apoptosis	  at	  an	  early	  stage.	  PS	  translocation	  to	  the	  outer	  cellular	  surface	  does	  not	  happen	  only	  during	  apoptosis,	  but	  also	  during	  necrosis.	  In	  the	  early	   stage	   of	   apoptosis,	   the	   cellular	   membrane	   is	   still	   intact;	   however,	   the	   membrane	   is	  disrupted	   during	   necrosis.	   Therefore,	   because	   this	   process	   is	   caused	   by	   early	  permeabilization	  of	  the	  cell	  membrane	  (lysis),	  necrosis	  is	  easily	  detected	  in	  vitro	  by	  exposure	  to	   a	   DNA	   binding	   dye	   such	   as	   PI.	   The	   exclusion	   of	   such	   a	   hydrophilic	   dye	   indicates	   cell	  viability.	  Cells	  in	  the	  metabolically	  active,	  early	  and	  middle	  stages	  of	  apoptosis	  do	  exclude	  the	  DNA	  binding	  dye,	  and	  are	  stained	  only	  by	  Annexin	  V-­‐FITC.	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2.2.3	  Cell	  sorting	  Hoechst	  33342	  solution	  (56µl	   from	  a	  stock	  of	  1mg/ml;	  AnaSpec	  Inc.,	  San	  Jose,	  CA,	  USA)	  was	  added	  onto	   FUCCI-­‐marked	   glioma	   cells	   in	   a	   10cm	  plate.	   After	   a	   30-­‐minute	   incubation,	   cells	  were	  harvested	  and	  analyzed	  with	  a	  FACS	  Aria	  III	  Cytometer.	  The	  detection	  channels	  used	  for	  FUCCI	  probes	  are	  FITC	  (488nm	  laser	  with	  530/30nm	  filter),	  and	  DS	  Red	  (405nm	  laser	  with	  a	  450/25nm	   filter).	   Hoechst	   33342	   was	   excited	   with	   UV	   radiation	   (405nm	   laser	   with	   a	  450/25nm	  filter).	  An	  85µm	  nozzle	  at	  35PSI	  was	  used.	  
2.3	  Imaging	  of	  cultured	  cells	  FUCCI-­‐transfected	   and	   selected	   cells	  were	   plated	   into	   Lab-­‐Tek	   Chambered	   Coverglass	  with	  phenol	  red-­‐free	  DMEM,	  10%	  FBS,	  and	  1%	  Penicillin/Streptomycin.	  A	  Spinning	  Disk	  Confocal	  Microscope,	   equipped	   with	   incubator,	   motorized	   cart,	   autofocus,	   and	   an	   AxioCam	   high-­‐resolution	   monochromatic	   camera	   was	   used	   for	   time-­‐lapse	   imaging.	   The	   microscope	  registered	  images	  sequences	  on	  3	  channels	  (FITC,	  DsRed,	  and	  DIC)	  at	  16	  bit	  every	  15	  minutes	  for	  4	  days.	  A	  PlanAPO	  20X	   (NA	  0,4)	  objective	  was	  used.	  All	   the	   images	  were	  acquired	  with	  AxioVision	  3.1	  software.	  
2.4	  Immunoblotting	  GBM	  cells	  were	  washed	  with	  PBS	  and	   lysed	   in	  buffer	  containing	  20nmol/L	  Tris-­‐HCl	  pH	  7.4,	  100nmol/L	  NaCl,	  300mmol/L	  sucrose,	  6mmol/L	  MgCl2,	  1mmol/L	  EGTA,	  0.5%	  Triton	  X-­‐100,	  1X	  PhosStop	  (Roche),	  and	  protease	   inhibitor	  cocktail	   (Roche)	   for	  one	  hour	  on	  roller	   in	  cold	  room.	  The	  concentration	  of	   the	   lysates	  was	  measured	  using	  Protein	  Assay	  reagent	  (Bio-­‐Rad	  Laboratories)	  and	  50μg	  of	  proteins	  were	  subjected	  to	  SDS-­‐PAGE	  electrophoresis	  and	  transfer	  onto	   Immuno-­‐Blot	  PVDF	  membranes	  (Bio-­‐Rad	  Laboratories).	  The	  membranes	  were	  blocked	  in	   1X	   TBS	   containing	   5%	   milk	   and	   0.05%	   Tween-­‐20	   for	   1	   hour,	   incubated	   with	   primary	  antibody	  diluted	   in	  blocking	  buffer	  overnight	  at	  4C˚,	  washed	  with	  1X	  TBS-­‐T	   for	   three	   times,	  and	  incubated	  with	  HRP-­‐conjugated	  secondary	  antibody	  (Santa	  Cruz	  Biotechnologies)	  diluted	  in	   blocking	   buffer	   for	   1	   hour.	   Protein	   expressions	   were	   detected	   by	   using	   ECL	   reagents	  (Amersham	   Pharmacia	   Biotech).	   Primary	   antibodies	  were	   obtained	   from	   Santa	   Cruz	   (beta-­‐
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actin	  and	  Geminin),	  Dharmacon	  (USP1),	  or	  Cell	  signaling	  (Cdt1,	  Cdc2,	  pCdc2,	  Cdc25c,	  pCdc25c,	  Chk1,	  pChk1,	  Chk2,	  pChk2,	  p53,	  Wee1,	  pWee1).	  
2.5	  Immunocytochemistry	  Cells	  were	   plated	   in	   Lab-­‐Tek	   2	   Chamber	   Slide	   (Thermo	   Scientific),	   treated	  with	   TMZ	   for	   3	  hours,	  and	  analyzed	  for	  Phospho-­‐Histone	  H2AX	  expression	  after	  2	  days.	  Cells	  were	  fixed	  with	  4%	  PFA	  for	  15	  minutes	  at	  room	  temperature,	  washed	  3	  times,	  and	  permeabilized	  with	  0.2%	  Triton	  for	  5	  minutes	  at	  room	  temperature.	  After	  washing	  them	  three	  times,	  cells	  were	  blocked	  with	  10%	  FBS	  in	  PBS	  for	  1	  hour,	   incubated	  with	  Anti-­‐gamma	  H2A.X	  phospho	  S139	  (Abcam)	  1:500	  in	  10%	  FBS	  +	  0.1%	  Triton	  in	  PBS	  for	  1	  hour	  at	  room	  temperature,	  washed	  3	  times,	  and	  incubated	  with	   488	   anti-­‐mouse	   secondary	   antibody	   (Invitrogen)	   1:500	   in	   10%	  FBS	  +	   0.1%	  Triton	   in	   PBS	   for	   30	   min	   at	   room	   temperature	   in	   dark.	   After	   3	   washes,	   the	   chamber	   was	  removed,	   and	   mounting	   media	   containing	   DAPI	   was	   added	   onto	   the	   cells.	   Slides	   were	  analyzed	  by	  Zeiss	  AMZ	  AxioObserver	  fluorescent	  microscope.	  






3.1	  Multiple	  TMZ	  treatments	  reduce	  glioma	  cells	  clonogenicity	  In	  order	  to	  determine	  whether	  different	  protocols	  of	  TMZ	  administration	  (1,	  2,	  or	  3	  doses	  in	  3	  consecutive	  days,	  3	  hours	  100μM	  TMZ	  per	  treatment)	  have	  different	  effects	  on	  the	  ability	  of	  glioma	  cells	  to	  form	  colonies	  and	  proliferate,	  we	  performed	  clonogenicity	  studies	  with	  TMZ-­‐sensitive	   U251	   and	   U87	   glioma	   cell	   lines.	   A	   single	   TMZ	   treatment	   can	   induce	   a	   10	   times	  reduction	   of	   colonies	   compared	   to	   controls.	   Colonies	   are	   further	   reduced	   of	   80%	   after	   a	  second	  dose,	  and	  undergo	  a	   further	  reduction	  of	  40%	  after	   the	  third	  administration	  (Figure	  3).	  	  
	   	  	   Figure	  3.	  Effects	  of	  multiple	  TMZ	  treatments	  on	  U251	  cells.	  Glioma	  cells	  have	  been	  treated	  with	  TMZ	  once,	  	   twice,	  or	  three	  times	  in	  three	  consecutive	  days.	  An	  equal	  number	  of	  cells	  have	  then	  been	  plated	  into	  6-­‐well	  	   plates.	  Colonies	  of	  at	  least	  50	  cells	  were	  counted	  after	  14	  days	  incubation	  at	  37°C	  and	  5%	  CO2.	  Compared	  	   to	   controls,	   colonies	   are	   reduced	   to	  20%,	  4%,	   and	  2.4%	  after	   1,	   2,	   and	  3	  TMZ	   treatments,	   respectively.	  	   Representative	  of	  three	  experiments.	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3.2	   Multiple	   TMZ	   treatments	   don’t	   significantly	   increase	   the	   number	   of	   G2/M	  
arrested	  cells	  in	  TMZ-­‐sensitive	  cells	  compared	  to	  single	  treatment	  We	  first	  confirmed	  G2/M	  arrest	  after	  a	  single	  TMZ	  treatment	  in	  U87	  and	  U251	  cells,	  and	  no	  arrest	   in	   TMZ-­‐resistant	   GBM8	   cells.	   Afterwards	  we	   focused	   on	   the	   effects	   of	  multiple	   TMZ	  treatments	  on	  cells	  undergo	  G2	  arrest.	  Therefore,	  we	  designed	  a	  study	  comparing	  3	  different	  treatment	  protocols	  (1,	  2,	  or	  3	  TMZ	  administrations	  in	  3	  consecutive	  days).	  Cells	  were	  initially	  exposed	  to	  100µM	  TMZ.	  TMZ	  was	  removed	  after	  3	  hours;	  cells	  were	  gently	  washed	  with	  PBS,	  and	  incubated	  in	  fresh	  medium.	  Cells	  were	  harvested	  and	  analyzed	  3	  days	  after	  the	  last	  TMZ	  treatment,	  as	  G2/M	  arrest	  is	  generally	  evident	  at	  this	  time	  (Figure	  4).	  	  
	  	  	   	  	   Figure	   4.	   GBM	   cell	   lines	   were	   plated	   in	   6-­‐well	   plates.	   After	   24-­‐hour	   incubation,	   TMZ	   100µM	   was	  	   administered	  for	  3	  hours	  daily,	  for	  1,	  2,	  or	  3	  consecutive	  days.	  Cells	  were	  harvested	  at	  day	  3	  and	  7	  after	  the	  	   last	  TMZ	  treatment	  for	  cytometry	  testing.	  







	  	   Figure	  5	  (pages	  15	  and	  16).	  Effect	  of	  multiple	  TMZ	  treatments	  on	  cell	  cycle	  progression.	  Panels	  I,	  II,	  and	  III	  	   are	   referred	   to	  U87,	  U251,	   and	  GBM8	   cells,	   respectively,	   3	   days	   after	   treatment.	  G1	   and	  G2	  peaks	   after	  	   cytometry	   processing	   are	   shown	   in	   quadrants	   A.	   Quadrants	   B	   and	   C	   graphically	   show	   cell	   cycle	  	   progression	  in	  control	  and	  TMZ-­‐treated	  cells.	  Representative	  of	  three	  experiments.	  
3.3	  TMZ	  induces	  apoptosis	  3	  days	  after	  treatment	  Apoptosis	  was	  studied	  with	  the	  Annexin	  V-­‐PI	  method.	  This	  technique	  allows	  visualizing	  cells	  during	  early	  and	  middle	  stages	  of	  apoptosis.	  Only	  a	  small	  amount	  of	  cells	  are	  apoptotic	  three	  days	  after	  TMZ	  treatment.	  Slight	  variations	  of	  response	   among	   cell	   lines	   may	   occur.	   Moreover,	   the	   differences	   between	   different	  administration	   protocols	   are	   statistically	   significant.	   Multiple	   TMZ	   treatments	   significantly	  increase	  apoptosis	  compared	   to	  controls	   (p=0.001)	  and	  single-­‐treatment	   (p=0.001)	   in	  TMZ-­‐sensitive	  cell	  lines	  (Figure	  6).	  U251	  is	  the	  most	  sensitive	  cell	  line,	  with	  a	  17.3%	  apoptotic	  cells	  after	   three	   TMZ	   administrations.	   Not	   surprisingly,	   TMZ-­‐resistant	   GBM8	   cell	   line	   does	   not	  undergo	  apoptosis.	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   Figure	  6.	  Rate	  of	  apoptotic	  cells	  3	  days	  after	  the	  last	  TMZ	  treatment.	  Representative	  of	  three	  experiments.	  
	  
3.4	   Apoptosis	   significantly	   increases	   7	   days	   after	   TMZ	   treatment,	   and	   with	  
multiple	  treatments	  Apoptosis	   significantly	   increases	   7	   days	   after	   TMZ	   treatment,	   with	   obvious	   variations	  depending	  on	  the	  different	  cell	  lines.	  Particularly,	  after	  three	  TMZ	  treatments,	  apoptotic	  cells	  are	   15.4%	   in	   U87	   and	   as	  much	   as	   30.7%	   in	   U251.	   Differences	   between	   the	   administration	  protocols	  are	  statistically	  significant	  (p<0.001)	  (Figure	  7).	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   Figure	  7.	  Rate	  of	  apoptotic	  cells	  7	  days	  after	  the	  last	  TMZ	  treatment.	  Representative	  of	  three	  experiments.	  
3.5	  Transfection	  with	  FUCCI	  does	  not	  change	  biological	  characteristics	  of	  U87	  cells	  It	  is	  interesting	  that	  the	  number	  of	  apoptotic	  cells	  increased	  when	  undergoing	  multiple	  TMZ	  treatments,	   although	   the	   cell	   cycle	   profiles	   were	   similar	   among	   the	   3	   different	   treatment	  protocols.	   Therefore,	   in	   order	   to	   address	   this	   question,	  we	  decided	   to	   use	   FUCCI	   probes	   to	  study	  the	  cell	  cycle	  progression	  in	  TMZ	  treated	  cells	  at	  the	  single-­‐cell	  level.	  U87	  cells	  were	  co-­‐transfected	  with	  both	  FUCCI	  plasmids	  and	  double	  sorted,	  as	  already	  explained.	  The	  G1-­‐	  and	  G2-­‐specificity	  of	  the	  constructs	  was	  confirmed	  with	  fluorescence-­‐activated	  cell	  sorting-­‐based	  DNA	  quantification	   and	   immunoblotting	   (Figure	   8).	  We	   confirmed	   that	   the	   two	   fluorescent	  replication-­‐licensing	  factors	  used,	  Cdt1	  and	  Geminin,	  are	  only	  present	  during	  G1	  and	  S/G2/M	  phases	   of	   the	   cell	   cycle,	   respectively	   (Figure	   8).	   Therefore,	   in	   U87FUCCI	   cells	   the	   color	   of	  nuclei	  correlates	  with	  the	  phase	  of	  the	  cell	  cycle.	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   Figure	  8.	  A)	  U87FUCCI	  cells	  distribution	  on	  a	  cytometric	  plot	   is	   similar	   to	  U87	  cells.	  B)	  U87FUCCI	  cells	  	   were	  sorted	  with	  a	  FACS	  Aria	  Cytometer	  basing	  on	  their	  fluorescence.	  The	  specificity	  of	  the	  two	  plasmids	  	   targeting	  G1	  and	  S/G2/M	  phases	  was	  confirmed	  measuring	  the	  DNA	  content	  of	  the	  subpopulations.	  C)	  The	  	   alternating	   expression	   of	   Cdt1	   and	   Geminin	   only	   in	   red-­‐fluorescent	   and	   green-­‐fluorescent	   cells,	  	   respectively,	   was	   verified	   by	  Western	   blot,	   confirming	   that	   they	   are	   selectively	   expressed	   only	   during	  	   G1	  and	  S/G2/M	  phases,	  respectively.	  D)	  Cell-­‐cycle	  regulation	  by	  SCFSkp2	  and	  APCCdh1	  maintains	  bistability	  	   between	  G1	  and	  S/G2/M	  phases.	  
Then,	  we	  verified	  that	  the	  characteristics	  of	  FUCCI	  transfected	  U87	  cells	  are	  similar	  to	  wild-­‐type	  U87	  cells	  in	  terms	  of	  response	  to	  TMZ.	  Similarly	  to	  U87	  cells,	  2	  days	  after	  TMZ	  exposure	  U87FUCCI	   cells	   undergo	   a	   G2-­‐arrest,	   which	   lasts	   at	   least	   until	   day	   5,	   as	   shown	   with	  fluorescence-­‐activated	   cell	   sorting-­‐based	   cell	   cycle	   analysis	   (Figure	   9A).	   We	   also	   showed	  phosphorylation	   of	   H2AX	   histone	   2	   days	   after	   TMZ	   treatment,	   confirming	   that	   TMZ	   causes	  DSBs	  in	  U87FUCCI	  cells	  (Figure	  9B).	  We	  also	  confirmed	  that	  TMZ-­‐induced	  activation	  of	  MMR	  promoted	  induction	  of	  Chk1,	  Chk2,	  and	  phosphorylation	  and	  inactivation	  of	  the	  Chk1	  kinase	  substrate	  Cdc25C.	  This	  event	  is	  temporally	  associated	  with	  phosphorylation	  of	  Cdc2	  and	  with	  the	   onset	   of	   TMZ-­‐induced	   G2-­‐M	   arrest	   [41,42].	   Consistently,	   we	   found	   a	   reduction	   of	   the	  inactive	  phosphorylated	  Wee1	  and	  the	  induction	  of	  p53,	  which	  have	  been	  associated	  with	  G2-­‐
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M	   checkpoint	   activation	   [43]	   (Figure	   9C).	   The	   expected	   effect	   of	   TMZ	   on	   U87FUCCI	   cells	  proliferation	  was	  also	  proved	  with	  a	  proliferation	  assay	  (Figure	  9D).	  	  
	  
	   Figure	  9.	  U87FUCCI	   cells	  have	   the	   same	  biological	   characteristics	   and	  behave	   similarly	   to	  U87	  cells.	  A)	  	   Fluorescence-­‐activated	  cell	  sorting-­‐based	  cell	  cycle	  analysis	  of	  TMZ-­‐induced	  G2	  arrest	  in	  U87FUCCI	  cells.	  	   B)	   Immunocytochemical	   analysis	   of	   H2AX	   histone	   phosphorylation	   after	   TMZ	   treatment.	   Secondary	  	   antibody	  only	  (*),	  untreated	  cells	  (0-­‐4),	  and	  TMZ-­‐treated	  cells	  (0’-­‐4’)	  are	  shown	  on	  each	  panel,	  from	  day	  0	  	   to	   day	   4	   after	  TMZ	   treatment.	   C)	  Western	  blot	   analysis	   using	   antibodies	   selective	   for	   pCdc25c,	   Cdc25c,	  	   pChk1,	  Chk1,	  pChk2,	  Chk2,	  pWee1,	  Wee1,	  pCdc2,	  Cdc2,	  p53,	  and	  actin.	  	   D)	   Proliferation	   assay	   using	   TMZ-­‐	   untreated	  and	  TMZ-­‐treated	  U87FUCCI	  cells.	  Representative	  of	  three	  experiments.	  





	   Figure	  10	  (previous	  page).	  A)	  Time-­‐lapse	   imaging	  of	  TMZ-­‐untreated	  and	  TMZ-­‐treated	  U87FUCCI	  cells.	  	   Green	  arrows	  point	   out	   green-­‐fluorescent	  G2-­‐phase	   cells;	   red	   arrows	   indicate	   red-­‐fluorescent	  G1-­‐phase	  	   cells;	  white	  arrows	  show	  cells	  during	  mitosis	  (M),	  which	  can	  appear	  either	  non-­‐fluorescent	  or	  yellow.	  B)	  	   Graphic	  representation	  of	  timing	  of	  cell	  cycle	  progression	  for	  cells	  visualized	  in	  panel	  A.	  C)	  Percentage	  of	  	   cells	  that	  didn’t	  divide	  in	  M	  phase	  in	  control	  cells	  and	  TMZ-­‐treated	  cells	  (mitotic	  slippage;	  14%	  and	  87%,	  	   respectively).	  We	   considered	   all	   cells	   that	  were	   traceable	   during	   the	   90-­‐hour	   experiment.	  We	   excluded	  	   divisions	   in	   the	   first	  24	  hours,	   as	  TMZ	  has	  no	  detectable	  effects	  during	   the	   first	  day	  after	   treatment.	  D)	  	   Table	  showing	  the	  average	  time	  (±standard	  deviations)	  spent	  in	  green	  (G2)	  phase	  by	  TMZ-­‐untreated	  and	  	   TMZ-­‐treated	  cells.	  
About	   86%	   of	   control	   cells	   progressed	   through	   the	   cell	   cycle	   as	   expected	   (Figure	   10C).	  Conversely,	  87%	  of	  TMZ-­‐treated	  cells	  progressed	  from	  green	  to	  red	  without	  dividing	  (Figure	  10A	  bottom,	  and	  Figure	  10C).	  Although	  those	  cells	  were	  still	  cycling,	  as	  confirmed	  by	  the	  color	  change	  during	  time-­‐lapse,	  they	  failed	  entering	  mitosis.	  Then,	  we	  focused	  on	  G2	  phase,	  and	  we	  found	  that	  most	  of	  U87	  cells	  don’t	  permanently	  arrest	  after	  TMZ	  treatment.	  However,	  the	  time	  spent	  during	  G2	  phase	  is	  longer	  after	  TMZ	  treatment	  compared	  with	  untreated	  cells	  (average	  G2-­‐time	  34±10	  hours	  and	  13±3	  hours,	  respectively.	  Figure	  10B	  and	  10D).	  
3.7	  USP1	  knockdown	  increases	  TMZ	  sensitivity	  in	  GBM	  cells	  In	  order	  to	  verify	  the	  role	  of	  USP1	  in	  glioma	  cells	  response	  to	  TMZ,	  a	  clonogenicity	  assay	  was	  performed	   plating	   different	   amounts	   of	   U251	   cells	   in	   6-­‐well	   plates,	   and	   in	   triplicate.	   Cells	  were	  treated	  with	  either	  a	  control	  or	  an	  anti-­‐USP1	  siRNA	  (Figure	  11).	  	  
	  
	   Figure	  11.	  USP1	  knockdown	  using	  siRNA.	  All	   the	  experiments	  were	  performed	  using	  cells	  with	  at	   least	  	   80%	  USP1	  knockdown.	  
In	   this	   way	   we	   showed	   that	   TMZ	   sensitivity	   is	   increased	   in	   USP1-­‐knockdown	   cells.	  Particularly,	  cells	  with	  low	  or	  absent	  USP1	  have	  a	  70%	  reduction	  in	  proliferation	  and	  colony	  formation	  ability	  (Figure	  12).	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   Figure	   12.	   Clonogenicity	   assay	   using	   U251	   cells	   treated	   with	   both	   TMZ	   and	   siRNA	   against	   USP1.	   A)	  	   Colonies	  of	  U251	  cells	  treated	  with	  either	  scramble	  or	  USP1	  siRNA,	  after	  TMZ	  exposure.	  B)	  USP1	  increases	  	   the	  resistance	  to	  TMZ	  in	  glioma	  cells.	  Compared	  to	  controls	  (cells	  treated	  with	  scramble	  siRNA	  and	  TMZ),	  	   cells	  with	  a	  low	  amount	  of	  USP1	  undergo	  a	  clonogenicity	  reduction	  of	  about	  70%.	  Representative	  of	  three	  	   experiments.	  
A	  similar	  study	  was	  performed	  using	  GBM8	  cells,	  which	  had	  been	  shown	  to	  be	  TMZ	  resistant	  in	   terms	   of	   both	   G2/M	   arrest	   and	   apoptosis	   induction.	   Surprisingly,	   USP1	   knock	   down	  increases	  TMZ	  effects	  also	   in	  GBM8	  cells,	   reducing	   their	  proliferation	  ability	  and	  decreasing	  colony	  formation	  capability	  (Figure	  13).	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   Figure	  13.	  A)	  Clonogenicity	  assay	  after	  TMZ	   treatment	  using	  GBM8	  cells	  exposed	   to	  either	  scramble	  or	  	   USP1-­‐targeting	   siRNA.	   B)	   Histogram	   showing	   that	   USP1	   knockdown	   alone	   causes	   a	   30%	   reduction	   of	  	   clonogenicity	  compared	  to	  controls.	  USP1	  knockdown	  enhances	  TMZ	  effect,	  with	  a	  clonogenicity	  decrease	  	   of	  more	  than	  80%,	  despite	  TMZ	  resistance.	  Representative	  of	  three	  experiments.	  
	  
3.8	  USP1	  knockdown,	  alone	  or	  in	  combination	  with	  TMZ,	  has	  no	  effect	  on	  cell	  cycle	  In	  order	  to	  verify	  whether	  the	  clonogenicity	  reduction	   induced	  by	  TMZ	  in	  USP1	  knockdown	  cells	  depends	  on	  cell	  cycle,	  we	  performed	  a	  fluorescence-­‐activated	  cell	  sorting-­‐based	  cell	  cycle	  analysis.	  We	  showed	  not	  only	   that	  USP1	  knockdown	  has	  no	  effect	  on	  cell	  cycle	  progression,	  but	  also	  that	  it	  does	  not	  significantly	  affect	  the	  TMZ-­‐related	  G2	  arrest	  (Figure	  14).	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   Figure	  14.	  Fluorescence-­‐activated	  cell	   sorting-­‐based	  cell	   cycle	  analysis	  on	  U251	  cells.	  Representative	  of	  	   three	  experiments.	  
	  




	   Figure	   15.	   Fluorescence-­‐activated	   cell	   sorting-­‐based	   apoptosis	   analysis	   on	   U251	   cells	   (Annexin	   V-­‐PI	  	   method).	  Representative	  of	  three	  experiments.	  
	  




4.	  Discussion	  and	  future	  directions	  




	   Figure	   17.	   The	   final	   activation	   of	   G2	   checkpoint	   is	   controlled	   by	   Cdk1	   (cyclin-­‐dependent	   kinase).	  	   When	  Cdk1	  is	  phosphorylated,	  it	  is	  unable	  to	  promote	  mitosis.	  Cdk1	  phosphorylation	  depends	  on	  proteins	  	   of	   Cdc25	   phosphatase	   family.	   In	   their	   active,	   non-­‐phosphorylated	   form,	   Cdc25A,	   Cdc25B,	   and	   Cdc25C	  	   dephosphorylate	   and	   activate	   Cdk1.	   Cdc25	   proteins	   are	   controlled	   by	   Chk1	   and	   Chk2.	  When	   Chk1	   and	  	   Chk2	  are	  activated	  by	  DNA	  damage,	  they	  phosphorylate	  and	  inactivate	  Cdc25	  proteins.	  
After	   determining	   that	   colony	   formation	   significantly	   decreases	   with	   the	   number	   of	   TMZ	  doses,	  we	   initially	   explored	   the	   possibility	   of	   an	   increased	  G2	   arrest	   to	   explain	   our	   results.	  However,	   the	   modest	   increase	   of	   G2/M	   arrest	   obtained	   with	   multiple	   TMZ	   doses	   is	   not	  statistically	   significant.	   Indeed,	   the	  percentage	   of	  G2-­‐arrested	   cells	   is	   very	   high	   (over	   80%)	  after	   the	   first	   dose	   of	   TMZ.	   Cell	   cycle	   arrest	   occurring	   after	   DNA	   damage	   is	   a	   defense	  mechanism	  that	  allows	  the	  cell	  enough	  time	  to	  repair	  it	  [5].	  However,	  the	  cell	  fate	  is	  extremely	  variable	   during	   and	   after	   arrest.	   The	   cells	   can	   actually	   survive	   after	   the	  DNA	  damage.	   This	  phenomenon	   often	   occurs	   in	   glioma	   cells	   particularly	   after	   a	   prolonged	   G2/M	   arrest.	  Conversely,	   the	   cells	   can	   also	   undergo	   mitotic	   catastrophe,	   necrosis,	   senescence,	   or	  autophagy,	  which	  ultimately	  lead	  to	  cell	  death.	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Apoptosis	  as	  a	  consequence	  of	  methylating	  drugs	  in	  gliomas	  has	  always	  been	  denied.	  In	  2007,	  a	  German	  group	  was	  able	   to	  detect	  apoptosis	   in	  glioma	  cells	  with	   the	  cytometric	  method	  of	  sub-­‐G1	  peak	  [79].	  They	  claimed	  apoptosis	  is	  a	  late	  effect	  of	  TMZ,	  which	  is	  visible	  only	  at	  least	  4	  days	  after	  drug	  administration.	  Apoptosis	  represents	  the	  ideal	  model	  for	  drug-­‐induced	  cell	  death,	  as	  its	  finely	  controlled	  steps	  can	  avoid	  any	  inflammatory	  response.	  For	  these	  reasons,	  we	  focused	  on	  the	  apoptotic	  response	  of	  glioma	  cells	  following	  different	  TMZ	  administration	  protocols,	  and	  the	  relation	  between	  apoptosis	  and	  cell	  cycle.	  We	   confirmed	   that	   apoptosis	   is	   possible	   in	   sensitive	   glioma	   cell	   lines	   after	   TMZ	  administration.	  Different	  to	  previously	  published	  papers,	  we	  showed	  that	  a	  limited	  amount	  of	  apoptotic	  cells	  are	  visible	  even	  3	  days	  after	  treatment.	  This	  difference	  can	  be	  due	  to	  the	  fact	  that	  Annexin	  V-­‐PI	  is	  a	  more	  sensitive	  method	  than	  sub-­‐G1	  peak	  to	  detect	  early	  apoptosis.	  Moreover,	  multiple	  TMZ	  treatments	  significantly	  enhance	  apoptosis,	  especially	  after	  the	  third	  administration.	  However,	  the	  amount	  of	  cells	  undergoing	  apoptosis	  is	  greater	  7	  days	  after	  the	  third	   administration.	   Also	   the	   differences	   between	   the	   administration	   schedules	   are	  statistically	  more	  evident	  at	  a	   late	  stage.	  Of	  course,	  response	  can	  vary	   in	  different	  cell	   lines,	  with	  an	  apoptosis	  rate	  ranging	  from	  15%	  in	  U87	  cells	  to	  more	  than	  30%	  in	  U251	  cells	  at	  day	  7.	   Therefore,	   apoptotic	   response	   after	   TMZ	   significantly	   increases	   in	   a	   time-­‐	   and	   schedule-­‐dependent	  manner,	  and	  is	  most	  clear	  in	  a	  late	  phase.	  It	  has	  been	  shown	  that	  O6MeG	  can	  activate	  an	  apoptotic	  pathway	  only	  in	  cells	  that	  are	  actively	  cycling	  and	  proliferating	  [79].	  Surprisingly,	  cells	  that	  are	  mostly	  arrested	  after	  the	  first	  TMZ	  treatment	  can	  undergo	  apoptosis,	  and	  apoptosis	  rate	  increases	  in	  relation	  with	  the	  number	  of	  treatments,	   although	   cell	   cycle	   is	   not	   significantly	   affected	   by	   administration	   schedule.	   In	  order	  to	  further	  explore	  these	  contrasting	  findings,	  and	  to	  find	  the	  relation	  between	  cell	  cycle	  and	  apoptosis,	  we	  moved	   from	  a	  population-­‐study	   to	  a	  single	  cell-­‐level.	  FUCCI	  probes	  allow	  tracking	  single	   live	  cells,	  visualizing	  cell	  cycle	  phases	  over	   time.	  The	  system	  is	  based	  on	  the	  fact	  that	  Cdt1	  and	  Geminin,	  which	  are	  replication-­‐promoting	  factors,	  are	  only	  present	  during	  specific	  phases	  of	   the	   cell	   cycle.	  Geminin	   is	   linked	   to	  a	  green-­‐fluorescent	  protein	  and	  stains	  S/G2/M	  cells.	  Cdt1	  is	  linked	  to	  a	  red-­‐fluorescent	  protein	  and	  stains	  G1	  cells	  (Figure	  8).	  As	   a	   preliminary	   study,	   the	   ability	   of	   the	   FUCCI	   system	   to	   accurately	   monitor	   cell	   cycle	  progression	  in	  glioma	  cells	  was	  first	  examined.	  U87	  cells	  transfected	  with	  constructs	  encoding	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mKO2-­‐hCdt1	   or	  mAG1-­‐hGem	  were	   first	   sorted	   for	   cells	   expressing	   red	   fluorescence	   (Cdt1),	  after	   which	   the	   cells	   were	   grown	   for	   24	   hours	   and	   resorted	   for	   cells	   expressing	   green	  fluorescence	  (Geminin).	  In	  this	  way	  we	  created	  a	  population	  containing	  and	  expressing	  both	  constructs.	  FACS-­‐based	  analysis	  of	  the	  mixed	  population	  revealed	  a	  high	  degree	  of	  correlation	  between	  red	  cells	  with	  2N	  DNA	  content	  and	  green	  cells	  with	  4N	  DNA	  content,	  consistent	  with	  the	  idea	  that	  Cdt1	  is	  a	  marker	  of	  cells	  in	  the	  G1	  phase	  of	  the	  cell	  cycle,	  and	  Geminin	  is	  a	  marker	  of	  cells	  in	  the	  G2	  phase.	  U87FUCCI	  cells	  were	  then	  exposed	  to	  TMZ	  and	  monitored	  for	  response.	  Similarly	  to	  U87	  cells,	  U87FUCCI	  cells	  exhibited	  H2AX	  foci	  beginning	  2	  days	  after	  TMZ	  exposure,	  and	  also	  activated	  the	  G2	  checkpoint,	  increasing	  phosphorylation	  of	  Chk1,	  cdc25C,	  cdc2,	  Wee1,	  and	  p53.	  In	  these	  cells,	  the	  DNA	  damage	  and	  the	  supposed	  G2/M	  arrest	  lasted	  for	  at	  least	  4	  days	  following	  TMZ	  treatment,	  and	  this	  observation	  is	  consistent	  with	  the	  inability	  to	  resolve	  TMZ-­‐induced	  DNA	  damage	   or	   to	   inhibit	   the	   checkpoint	   activation.	   Consistent	   with	   previous	   observations,	   the	  cells	  also	  underwent	  what	  appeared	  to	  be	  a	  G2	  arrest	  with	  cells	  accumulating	  with	  4N	  DNA	  beginning	  2	  days	  after	  TMZ	  exposure	  and	  remaining	  arrested	  through	  the	  4	  days	  of	  the	  study	  [41-­‐43].	  	  In	  parallel	   studies,	   control	   and	  TMZ-­‐treated	   cells	  pre-­‐selected	   for	   expression	  of	  both	  FUCCI	  constructs	   were	   grown	   in	   control	   environment	   chambers	   and	   followed	   by	   time-­‐lapse	  fluorescence	   microscopy	   for	   cell	   cycle	   progression.	   In	   control	   cells,	   the	   initial	   unsorted,	  unsynchronized	  population	  was	  a	  mixture	  of	  red	  and	  green	  cells	  consistent	  with	  distribution	  across	   all	   phases	   of	   the	   cell	   cycle.	   Following	   individual	   cells	   over	   the	   90	   hours	   of	   the	  experiment	   revealed	   that	   the	   cells	   toggled	   between	   red	   and	   green	   expression	   with	   the	  S/G2/M	  (green)	  phases	  of	   the	  cell	  cycle	   lasting	  an	  average	  of	  12-­‐14	  hours	  and	  the	  G1	  (red)	  phase	  lasting	  an	  average	  of	  20	  hours.	  Conversely,	  TMZ-­‐sensitive	  glioma	  cells	  do	  not	  undergo	  prolonged	  G2	  arrest	  but	  rather	  arrest	  at	  the	  G2	  checkpoint	  for	  less	  than	  48	  hrs.	  Furthermore,	  these	  cells	  do	  not	  bypass	  the	  checkpoint	  and	  die	  during	  mitosis,	  but	  rather	  in	  the	  presence	  of	  an	  activated	  G2	  checkpoint,	  skip	  mitosis	  entirely,	  re-­‐enter	  the	  cell	  cycle	  at	  the	  next	  G1	  phase,	  replicate	   their	   DNA,	   and	   repeat	   the	   cycle,	   ultimately	   giving	   rise	   to	   TMZ-­‐resistant	   polyploid	  cells.	  Actually	  mitosis	  is	  a	  delicate	  phase	  of	  the	  cell	  cycle.	  Cells	  skipping	  mitosis	  might	  possibly	  avoid	   cell	   death	   and	  become	  TMZ-­‐resistant.	   These	   findings	   are	   consistent	  with	   FACS-­‐based	  cell	   cycle	   data	   showing	   a	  G2	   arrest,	   as	   FACS	   offers	   just	   a	   static	   picture	   of	   the	   treated	   cells,	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which	  are	  not	  arrested,	  but	  delayed	  in	  G2	  phase.	  Of	  course,	  these	  results	  need	  to	  be	  confirmed	  in	   more	   TMZ-­‐sensitive	   and	   TMZ-­‐resistant	   cell	   lines.	   Moreover,	   it	   would	   be	   interesting	  verifying	  if	  cells	  undergoing	  mitotic	  slippage	  can	  still	   form	  colonies.	  This	  would	  suggest	  that	  mitotic	  failure	  is	  not	  only	  a	  resistance	  mechanism	  for	  the	  single	  cell,	  but	  also	  a	  prerequisite	  for	  regrowth.	  The	   G2	   checkpoint	   is	   part	   of	   a	   defense	   system	   used	   by	   the	   cells	   to	   resist	   from	   genotoxic	  insults.	  In	  the	  presence	  of	  DSBs	  and	  stalled	  replication	  forks,	  the	  ataxia-­‐telangiectasia	  mutated	  (ATM)	   and	   the	   ataxia-­‐telangiectasia	   Rad3-­‐related	   (ATR)	   activate	   checkpoints	   transmitting	  signals	  to	  Chk1	  and	  Chk2	  [11,37,90,95].	  ATM	  and	  ATR	  transmit	  signals	  to	  major	  downstream	  targets,	   such	   as	   Chk1	   and	  Chk2	   [44].	   These	   kinases	   negatively	   regulate	   Cdc25	  phosphatase	  family	  proteins	   that	  dephosphorylate	  Cdks	   involved	   in	   the	  cell	   cycle	   transition	   [7].	  This	  can	  lead	  to	  failure	  of	  the	  cell	  to	  enter	  mitosis	  and	  proceed	  to	  G1	  phase	  of	  the	  cell	  cycle	  (Figure	  17).	  	  Mitotic	   slippage	   has	   already	   been	   described	   as	   one	   of	   the	   three	   causes	   of	   tetraploidization	  during	   tumorigenesis,	   along	   with	   cell	   fusion	   and	   failure	   to	   complete	   cytokinesis	   [18,33].	  Tetraploidization	   has	   been	   proposed	   as	   an	   intermediate	   step	   toward	   aneuploidy	   in	   human	  cancer	   [88].	   Aneuploidy	   is	   expected	   to	   allow	   tumor	   cells	   to	   sustain	   a	   higher	   incidence	   of	  mutations,	   thereby	   increasing	   the	  probability	   of	   adaptive	   changes	   [93].	   For	   this	   reason,	  we	  hypothesize	   that	   TMZ-­‐induced	   aneuploidy	   could	   represent	   a	   mechanism	   of	   resistance	   for	  tumor	   cells	   treated	  with	  methylating	   agents.	   It	   has	  been	   shown	   that	  permanently	  damaged	  telomeres	  can	  induce	  bypass	  of	  mitosis	  and	  endoreduplication	  [19].	  In	  a	  recent	  paper,	  Hyun	  et	  al	   showed	   that	  DNA	  damage	   induces	  ATM/Chk1	  pathway-­‐dependent	   re-­‐replication	  without	  cell	   division	   in	   HeLa	   cells	   [46].	   As	   TMZ	   activates	   the	   same	   pathway,	   we	   hypothesize	   that	  ATM/Chk1	   pathway	   can	   be	   involved	   to	   explain	   our	   findings	   as	  well.	   G2	   checkpoint	   is	   also	  regulated	   by	  Wee1	   [26,52,54,71,97,100].	   G2	   checkpoint	   abrogation	   by	  Wee1	   inhibition	   has	  been	  shown	  to	  result	  in	  mitotic	  catastrophe	  due	  to	  unrepaired	  DSBs	  in	  glioblastoma	  [60].	  All	  these	  molecules	  are	  involved	  in	  promoting	  mitosis	  and	  are	  affected	  by	  TMZ.	  Therefore,	  future	  studies	  should	  address	  the	  possible	  role	  of	  such	  pathways	  in	  TMZ-­‐induced	  mitotic	  slippage	  in	  GBM.	  A	  better	  comprehension	  of	  the	  involved	  mechanisms	  can	  potentially	  offer	  new	  tools	  to	  improve	   treatment	   of	   glioblastoma.	   For	   example,	   it	   would	   be	   worth	   verifying	   whether	  pushing	  cells	  into	  mitosis	  might	  increase	  the	  cytotoxic	  potential	  of	  TMZ.	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Besides	  opening	  new	  perspectives	  to	  explain	  the	  molecular	  effects	  of	  TMZ	  in	  glioma,	  mitotic	  failure	   could	   also	   be	   an	   intriguing	  way	   to	   find	   an	   explanation	   for	   increased	   apoptosis	   after	  multiple	  TMZ	  treatments.	  Apoptosis	  has	  been	  described	  as	  an	  abortive	  entry	   into	  cell	   cycle,	  given	  the	  morphological	  similarities	  between	  apoptosis	  and	  mitosis	  [85].	  A	  number	  of	  studies	  have	  associated	  molecules	  that	  are	  clearly	  linked	  to	  cell	  proliferation,	  such	  as	  Myc	  or	  E2F-­‐1,	  with	  apoptosis	  [29,84].	  Moreover,	  apoptosis	  has	  been	  described	  as	  a	  possible	  consequence	  of	  mitotic	  failure	  [12,16,47,103].	  New	  studies	  with	  FUCCI-­‐expressing	  cells	  treated	  with	  multiple	  TMZ	  doses	  might	  help	  clarifying	  this	  phenomenon.	  	  DNA	  repair	  in	  response	  to	  methylating	  agents	  such	  as	  temozolomide	  has	  recently	  been	  shown	  to	  require	  monoubiquitination	  of	  PCNA	  and	  FANCD2,	  and	  loss	  of	  either	  protein,	  or	  inhibition	  of	   their	   monoubiquitination,	   enhances	   methylating	   agent-­‐induced	   toxicity	   [67,72].	  Monoubiquitination	  of	  both	  proteins	  is	  reversed	  by	  the	  deubiquitanse	  USP1,	  suggesting	  that	  USP1	  may	  be	  a	  key	   controller	  of	   temozolomide	   sensitivity	   [39].	  Actually,	  ubiquitination	  not	  only	   marks	   the	   proteins	   directed	   to	   degradation,	   but	   it	   can	   also	   lead	   them	   to	   specific	  subcellular	  localizations	  and	  promote	  protein-­‐protein	  interactions	  [45].	  	  Because	  USP1	  has	   the	  potential	   to	   deubiquitinate	  PCNA	  and	  FANCD2	  and	   to	   suppress	  DNA	  repair,	   we	   anticipated	   that	   USP1	   levels	   in	   GBM	   might	   be	   lower	   than	   in	   normal	   controls.	  	  Analysis	   of	   expression	   array	   data	   from	   three	   separate	   databases	   however	   suggested	   that	  USP1	   mRNA	   levels	   were	   consistently	   elevated	   in	   a	   large	   percentage	   of	   GBM	   [34,73,92].	  Consistent	  with	  this	  observation,	  USP1	  mRNA	  and	  protein	  levels	  were	  high	  in	  most	  GBM	  cell	  lines	  examined.	  	  siRNA-­‐mediated	  suppression	  of	  USP1	  had	  no	  effect	  on	  cell	  cycle	  progression	  or	  the	  extent	  of	  temozolomide-­‐induced	  G2	  arrest,	  suggesting	  that	  the	  extent	  of	  temozolomide-­‐induced	   DNA	   damage	   in	   USP1-­‐deficient	   cells	   was	   comparable	   to	   that	   in	   control	   cells.	  	  Surprisingly,	   while	   USP1	   knockdown	   alone	   had	   no	   effect	   on	   cell	   death,	   it	   increased	  temozolomide-­‐induced	   loss	  of	   clonogenicity	  both	   in	   cells	   that	  were	   sensitive	  or	   resistant	   to	  temozolomide.	   Further	   examination	   of	   the	   mechanism	   of	   cell	   death	   suggested	   that	   while	  control	   cells,	   control	   cells	   exposed	   to	   TMZ,	   or	   USP1-­‐suppressed	   cells	   rarely	   underwent	  apoptotic	   cell	   death,	   temozolomide-­‐treated	   cells	   in	   which	   USP1	   levels	   were	   suppressed	  underwent	   high	   rates	   of	   apoptosis.	   These	   preliminary	   results	   raise	   the	   question	   about	   the	  molecular	   pathways	   involved	   by	   USP1	   in	   the	   prevention	   of	   apoptosis.	   Further	   studies	   will	  have	  to	  first	  clarify	  the	  role	  of	  MGMT	  and	  caspases	  cascade.	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The	  deubiquitinase	  USP1	  has	  been	   indirectly	   suggested	   to	   inhibit	   the	   function	  of	  PCNA	  and	  FANCD2,	  to	  inhibit	  the	  repair	  of	  methylating	  agent-­‐induced	  DNA	  damage,	  and	  to	  sensitize	  cells	  to	  DNA	  damage	  [48]	  (Figure	  18).	  	  
	  	   Figure	  18.	  PCNA	  pathway	  regulation.	  PCNA	  is	  an	  structural	  and	  functional	  component,	  which	  is	  essential	  	   for	  the	  stability	  of	  DNA	  replication	  fork.	  Monoubiquitinated	  PCNA	  mediates	  DNA	  translesional	  synthesis.	  	   After	   DNA	   damage,	   Rad6	   and	   Rad18	   (E2-­‐E3	   complex)	   allow	   PCNA	   monoubiquitination.	  	   Monoubiquitinated	   PCNA	   increases	   its	   affinity	   for	   translesion	   polymerases,	   and	   the	   cell	   can	   therefore	  	   bypass	  DNA	  lesion	  and	  replicate.	  PCNA	  ubiquitination	  is	  controlled	  by	  USP1	  in	  human	  cells.	  
When	   PCNA	   is	   not	   monoubiquitinated,	   cells	   are	   more	   sensitive	   to	   UV	   radiations	   and	  methylmethane	  sulfonate	  (MMS)	  [67].	  As	  the	  levels	  of	  PCNA	  monoubiquitination	  are	  inversely	  related	  to	  USP1	  levels	  after	  UV-­‐induced	  DNA	  damage,	  USP1	  expression	  has	  been	  associated	  to	  a	  reduced	  survival	  of	  cells	  after	  genotoxic	  damage	  [67].	  Conversely,	  after	  treatment	  with	  MMS	  and	  mitomycin	  (MMC),	  PCNA	  monoubiquitination	  has	  not	  been	  related	  to	  a	  reduction	  of	  USP1,	  which	  rather	  increases	  at	  a	   later	  stage	  [67].	  Two	  hypotheses	  have	  been	  proposed	  to	  explain	  these	   results.	  Monoubiquitinated	   PCNA	   could	   somehow	   sequester	   and	   ultimately	   allow	   the	  removal	  of	  USP1.	  Otherwise,	  different	  types	  of	  DNA	  damage	  could	  differently	  modulate	  USP1	  activation	   acting	   on	   UAF1	  molecule	   [67].	   Basing	   on	   these	   divergent	   observations,	   it	   is	   not	  possible	   to	  assign	  a	  clear	  role	   to	  USP1	  regarding	  the	  PCNA-­‐mediated	  cellular	  response	  after	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genotoxic	  damage.	  Another	  study	  showed	  that	  USP1	  suppression	  is	  well	   tolerated	  in	  human	  cells,	  and	  gives	  resistance	  to	  DNA	  damage,	  increasing	  monoubiquitinated	  FANCD2	  levels	  [68].	  The	   FA	   pathway	   (Fanconi	   Anemia	   pathway)	   has	   actually	   a	   crucial	   role	   for	   the	   repair	   of	  secondary	   lesions,	   as	   DNA	  DSBs	   and	   replication	   arrest,	   produced	  when	   the	   primary	   lesion	  O6MeG	   is	   processed	  by	  MMR	   system	   [2,53,63,102]	   (Figure	  19).	  However,	   the	   same	   authors	  report	   that	   the	   impossibility	   to	   deubiquitinate	   FANCD2	   may	   lead	   to	   homologue	  recombination	   without	   DNA	   damage,	   and	   ultimately	   to	   chromosome	   instability.	   Recently,	  Oestergaard	  et	  al	  showed	  that	  in	  chicken	  cells	  the	  persistent	  monoubiquitination	  of	  FANCD2	  due	  to	  USP1	  knockdown	  causes	  a	  hypersensitivity	  to	  DNA	  crosslinking.	  Therefore,	  the	  authors	  propose	  for	  USP1	  a	  function	  of	  activator,	  and	  not	  inhibitor,	  of	  FA	  pathway.	  In	  this	  model,	  USP1	  would	   limit	   the	   accumulation	   of	   FANCD2	  on	   chromatine	   only	   after	  DNA	  damage	   [72].	  New	  studies	  are	  needed	  to	  understand	  the	  role	  of	  USP1	  also	  in	  the	  regulation	  of	  FANCD2.	  
	  
	   Figure	  19.	  FA	  pathway	  regulation.	  Green	  arrows	  are	  activating,	  red	  arrows	  are	  inhibiting	  stimuli.	  1)	  ATR	  	   activates	   the	   pathway	   by	   phosphorylating	   FANCI,	   FANCD2,	   FANCA,	   and	   probably	   FANCG.	   2)	   USP1,	  	   associated	  with	  its	  activator	  UAF1,	  removes	  monoubiquitin	  from	  FANCD2	  and	  FANCI,	  therefore	  inhibiting	  	   the	  pathway.	  3)	  During	  mitosis,	  Plk1	  phosphorylates	  FANCM,	   therefore	  creating	  a	   link	  site	   for	  ubiquitin	  	   ligase	   βTRCP.	   FANCM	   is	   then	   monoubiquitinated	   and	   is	   degraded	   by	   proteasome.	   4)	   Chk1-­‐dependent	  	   phosphorylation	  of	  FANCE	  causes	  its	  degradation	  (Moldovan	  GL,	  D’Andrea	  AD,	  2009	  [61]).	  
In	   human	   cells,	   USP1	   knockdown	   has	   been	   associated	   with	   a	   higher	   survival	   after	   DNA	  damage.	  The	  present	  studies,	  however,	  show	  that	  primary	  GBM	  and	  GBM	  cell	  lines	  have	  high	  levels	  of	  USP1,	  and	  that	  rather	  than	  sensitizing	  cells	  to	  DNA	  damaging	  agents,	  USP1	  appears	  to	  suppress	   latent	   apoptotic	   pathways	   and	   to	   protect	   cells	   from	   temozolomide-­‐induced	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